Dimension led a $115m Series B round in Aspect Biosystems.

Dimension, a multistage investment firm, led a $115m Series B round in Aspect Biosystems, a biotechnology company pioneering the development of bioprinted tissue therapeutics as a new category in regenerative medicine, with participation from Novo Nordisk, Radical Ventures, InBC, Pallasite Ventures, Pangaea Ventures, Rhino Ventures, and T1D Fund. “I am incredibly proud of the progress our team is making on our mission to develop disease-modifying treatments for people living with serious diseases. We are thrilled to partner with Dimension and this exceptional, mission-aligned investor syndicate. We are grateful for their support as we embark on our next chapter dedicated to transforming patient outcomes for the better,” Tamer Mohamed, Aspect Biosystems Founder and CEO.